Neurocrine Biosciences Inc

2026. g. 25. sept. 20:07 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for six sessions, significantly below the 20-day moving average amid broader market declines.

2026. g. 24. sept. 20:07 UTC

Neurocrine Biosciences Inc shares fell, marking the sixth consecutive session of lower closes and remaining significantly below the 20-day moving average.

2026. g. 23. sept. 20:01 UTC

Neurocrine Biosciences Inc shares fell, continuing a downward trend for four sessions and trading significantly below the 20-day moving average.

2026. g. 21. sept. 20:06 UTC

Neurocrine Biosciences shares fell sharply after RBC Capital cut its price target to $187.00 from $198.00, citing concerns over near-term performance.

2026. g. 18. sept. 20:02 UTC

Neurocrine Biosciences Inc shares fell sharply, breaking a trend of higher daily closes following a decline since Thursday's close.

2026. g. 17. sept. 19:54 UTC

Neurocrine Biosciences Inc's stock is rising as economic data shows unexpected declines in jobless claims and stronger manufacturing growth, despite weaker housing indicators.

2026. g. 16. sept. 23:51 UTC

Neurocrine Biosciences Inc is higher in after-market trading, supported by strong U.S. retail sales data, despite disappointing long-term TIC flows of $27.9 billion.

2026. g. 15. sept. 23:06 UTC

Neurocrine Biosciences Inc shares are trading lower in after-market hours. Broader market conditions may be influencing sentiment amid rising inflation concerns.

2026. g. 10. sept. 20:07 UTC

Neurocrine Biosciences Inc shares are advancing, supported by a steady upward trajectory. The stock remains above recent averages despite an earlier pullback.

2026. g. 2. sept. 19:56 UTC

Neurocrine Biosciences Inc is trading higher today, reaching a morning high before pulling back. No specific news was identified to explain the movement.

2026. g. 1. sept. 20:08 UTC

Neurocrine Biosciences Inc shares are higher today, continuing an upward trend since Monday's close amid sustained investor interest. No specific news was identified.

2026. g. 31. aug. 20:07 UTC

Neurocrine Biosciences shares are trading roughly flat amid inflation concerns and expectations for a potential interest rate hike following comments from Warsh at Jackson Hole.

2026. g. 28. aug. 20:02 UTC

Neurocrine Biosciences Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and no specific company news identified.

2026. g. 27. aug. 20:07 UTC

Neurocrine Biosciences Inc shares are lower today, with no specific news driving the decline despite positive broader market labor data.

2026. g. 26. aug. 20:08 UTC

Neurocrine Biosciences advances after FDA accepts NBI-1117567 application, triggering a $10 million milestone payment to partner Nxera. Shares pulled back from session highs earlier.

2026. g. 25. aug. 20:07 UTC

Neurocrine Biosciences Inc shares are higher, reflecting a broader market trend amid lower oil prices and Treasury yields. The stock remains below its 20-day moving average.

2026. g. 24. aug. 22:21 UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026. g. 21. aug. 19:56 UTC

Neurocrine Biosciences Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average.

2026. g. 20. aug. 20:06 UTC

Neurocrine Biosciences Inc shares are lower today amid rising U.S. Treasury yields and higher crude oil prices, with no specific company news identified.

2026. g. 19. aug. 19:26 UTC

Neurocrine Biosciences Inc is trading higher today, continuing an upward trend since Tuesday's close. No specific news was identified to explain the movement.

2026. g. 14. aug. 19:16 UTC

Neurocrine Biosciences Inc is trading higher during Friday's session, despite earlier pulling back from a session high amid cautious investor sentiment.

2026. g. 13. aug. 20:02 UTC

Neurocrine Biosciences shares decline as Morgan Stanley lowers price target to $182, citing safety concerns over VYKAT XR and reports of serious adverse events.

2026. g. 12. aug. 21:11 UTC

Neurocrine Biosciences published positive KINECT-PRO™ study results, yet shares are lower in after-market hours, continuing a trend of declining daily closes.

2026. g. 10. aug. 19:36 UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, contributing to a rise in shares during the session. The stock remains below its 20-day moving average.

2026. g. 7. aug. 19:46 UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

2026. g. 6. aug. 19:36 UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

2026. g. 5. aug. 23:46 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

2026. g. 4. aug. 19:26 UTC

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

2026. g. 3. aug. 20:51 UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

2026. g. 31. jūl. 23:56 UTC

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.